Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of people who were overweight or obese, it said on Tuesday. The drugmaker's shares, however,

Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year in a critical mid-stage trial. The company said it did not observe a plateau, which indicates the potential for further weight loss beyond 52 weeks.

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.